+ Watch EXAS
on My Watchlist
An applied genomics company that develops proprietary DNA-based technologies for use in the detection of cancer.
Medicare reimbursement rate of 504 / test!!!
Proven by the Mayo clinic. Strong reimbursement rates from Medicare are approved at $502 per test, and market will be between 2 million to 8 million tests per year.
Huge advance in colonrectal cancer detection that will obviate the need for a colonostophy. This test will be BIG! It saves money ($2,500 vs $500), saves the patient the VERY unpleasant experience of a colonsoptophy an it is highly accurate.
Favorable CMS pricing decision should be coming soon.
According to reports this non-invasive proceedure can detect 90% of stage 1 and stage 2 colorectal cancers at an early treatable stage. FDA has just approved it. With a low 10% false positives and its low cost when compared with colonoscopy. It looks like a winner as we look for cheaper ways to provide quality care.
FDA approval seems inevitable. Even if their current sales channel fails to fully mature or their reimbursement rate falls too low the current price is low enough to make them an acquisition candidate.
On the rec of Kirk Spano. Upon FDA approval and subsequent execution of business plan, they will have a way to prevent most of the 50,000 yearly deaths due to colorectal cancers not found early enough. This is the 2nd most deadly cancer and yet also the most preventable with screening as it can take ten full years to develop. Market is large and the company may also develop other stool based tests for detecting other forms of cancer, opening more markets and more importantly saving more lives. Strong and experienced management and strong balance sheet.
Hoping their participation at the Baird conference yields some business partnerships.
Look at their product. Who will really use this?
Thanks to Portefeuille I caught a nice rebound on Exact last week as a negative reaction to the DeeP-C data mysteriously reversed itself. I still have 100 shares of the stock with cost basis 7 that I'm just waiting for Portefeuille to tell me what to do with, but it isn't enough of a position to stop me from betting against it in CAPS. A 600M market cap is way too much for unconvincing sensitivity and specificity data that don't provide a convincing basis for widespread adoption of the Cologuard test. Exact is once again a trader's football and I expect the stock to move with the winds until a concrete catalyst emerges.
Fallen too far. Once FDA approves, EXAS will become much more competitive and might get bought.
Very important screening test
The graying of America makes one high on pharmaceuticals.
Boomers getting old."Can I stick this in your butt?""No, but here's some poo."
Blood based tests don't find PRE-CANCERS with any amount of accuracy. The ColoGuard(EXAS) test is done in your own home in 1 minute, no doctor, no office visit, no needle stuck in your arm. The accuracy of the stool based DNA test is far better than any blood based test.10,000 person Phase 3 FDA/Mayo clinic validation study will be complete in this quarter for top line results reported in Q4 THIS year.
My belief is that a stool DNA test will not be successful. There are several blood-based diagnostic tests for CRC that look promising, and much more patient friendly.
went up 216 % for portefeille.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions